For the quarter ending 2026-03-31, FBIOP has $356,874K in assets. $154,500K in debts. $255,841K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 255,841 | 79,381 | 86,218 | 74,386 |
| Assets held for sale | - | 0 | 0 | 0 |
| Accounts receivable, net | 24,992 | 29,783 | 17,983 | 15,644 |
| Inventory | 9,292 | 9,624 | 11,818 | 12,852 |
| Other receivables | 516 | 158 | 142 | 558 |
| Prepaid expenses and other current assets | 4,839 | 4,895 | 2,342 | 6,956 |
| Total current assets | 295,480 | 123,841 | 118,503 | 110,396 |
| Property, plant and equipment, net | 2,426 | 2,519 | 2,611 | 2,704 |
| Operating lease right-of-use asset, net | 11,822 | 12,302 | 12,321 | 12,817 |
| Restricted cash | 1,220 | 1,220 | 1,220 | 1,220 |
| Equity investments, at fair value | 18,707 | 17,660 | - | - |
| Intangible assets, net | 26,479 | 27,605 | 28,670 | 29,734 |
| Other assets | 740 | 401 | 18,082 | 3,024 |
| Total assets | 356,874 | 185,548 | 181,407 | 159,895 |
| Accounts payable and accrued expenses | 92,986 | 47,125 | 45,171 | 48,576 |
| Income taxes payable | 5,418 | 356 | 1,005 | 984 |
| Common stock warrant liabilities | 0 | 1 | 2 | 0 |
| Operating lease liabilities, short-term | 2,221 | 2,127 | 2,129 | 2,140 |
| Partner company notes payable, short-term | 2,500 | - | 5,625 | 3,750 |
| Partner company installment payments - licenses, short-term | - | 0 | 0 | 0 |
| Other current liabilities | 268 | 135 | 135 | 2,071 |
| Total current liabilities | 103,393 | 49,744 | 54,067 | 57,521 |
| Notes payable, long-term | 36,878 | 52,417 | 47,774 | 50,026 |
| Operating lease liabilities, long-term | 12,028 | 12,672 | 12,765 | 13,303 |
| Partner company redeemable perpetual preferred liability | 0 | 7,085 | - | - |
| Other long-term liabilities | 2,201 | 1,447 | 1,616 | 1,662 |
| Total liabilities | 154,500 | 123,365 | 116,222 | 122,512 |
| Cumulative redeemable perpetual preferred stock, 0.001 par value, 15,000,000 authorized, 5,000,000 designated series a shares, 3,427,138 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively, liquidation value of 25.00 per share | 3 | 3 | 3 | 3 |
| Common stock, 0.001 par value, 200,000,000 shares authorized, 33,186,671 and 31,364,094 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 33 | 31 | 31 | 30 |
| Additional paid-in-capital | 785,851 | 783,891 | 785,943 | 779,856 |
| Accumulated deficit | -623,679 | -734,052 | -730,115 | -735,965 |
| Total stockholders' equity attributed to the company | 162,208 | 49,873 | 55,862 | 43,924 |
| Non-controlling interests | 40,166 | 12,310 | 9,323 | -6,541 |
| Total stockholders' equity | 202,374 | 62,183 | 65,185 | 37,383 |
| Total liabilities and stockholders' equity | 356,874 | 185,548 | 181,407 | 159,895 |
Fortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc. (FBIOP)